Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Launched by GALDERMA R&D · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the real-world effectiveness of a medication called nemolizumab (also known as Nemluvio®) for adults with moderate to severe prurigo nodularis, a skin condition that causes itchy lumps. The study aims to see how well this treatment works for patients by gathering feedback from both doctors and patients after six months of treatment. While the trial is not yet recruiting participants, it will include adults aged 18 and older who are starting nemolizumab for the first time, provided their doctor agrees that this is the right treatment for them.

To be eligible for the study, participants must not have any medical reasons that would prevent them from using nemolizumab, and they should not have received any other investigational treatments in the three months before starting this trial. Additionally, they must be able to understand the study information and complete questionnaires about their experience. If you or someone you know is dealing with prurigo nodularis and is interested in participating, this trial could provide valuable insights into how effective nemolizumab is in everyday clinical practice.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
• • Participants greater than or equal to (\>=) 18 years of age.
• • Participants who signed the written informed consent form (ICF).
• Exclusion Criteria:
• • Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
• • Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
• • Participants who received nemolizumab previously.
• • Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.